

62 Rec'd PCT/PTO 09 JUL 1998

FORM PTO-1390  
(REV 10-96)

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

TRANSMITTAL LETTER TO THE UNITED STATES  
DESIGNATED/ELECTED OFFICE (DO/EO/US)  
CONCERNING A FILING UNDER 35 U.S.C. 371

WPT 0114 PUSA

U.S. APPLICATION NO. (if known, see 37 C.F.R. 1.5)

09/101423

INTERNATIONAL APPLICATION NO.

PCT/GB97/00074

INTERNATIONAL FILING DATE

10 January 1997

PRIORITY DATE CLAIMED

10 January 1996

TITLE OF INVENTION

METASTASIS INDUCING DNA'S

APPLICANT(S) FOR DO/EO/US

RUDLAND, Philip Spencer and BARRACLOUGH, Barry Roger

Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:

1. ☒ This is a **FIRST** submission of items concerning a filing under 35 U.S.C. 371.
2. ☐ This is a **SECOND** or **SUBSEQUENT** submission of items concerning a filing under 35 U.S.C. 371.
3. ☐ This express request to begin national examination procedures (35 U.S.C. 371(f)) at any time rather than delay examination until the expiration of the applicable time limit set in 35 U.S.C. 371(b) and PCT Articles 22 and 39(1).
4. ☒ A proper Demand for International Preliminary Examination was made by the 19th month from the earliest claimed priority date.
5. ☒ A copy of the International Application as filed (35 U.S.C. 371(c)(2))
  - a. ☐ is transmitted herewith (required only if not transmitted by the International Bureau).
  - b. ☒ has been transmitted by the International Bureau.
  - c. ☐ is not required, as the application was filed in the United States Receiving Office (RO/US)
6. ☐ A translation of the International Application into English (35 U.S.C. 371(c)(2)).
7. ☒ Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3))
  - a. ☐ are transmitted herewith (required only if not transmitted by the International Bureau).
  - b. ☐ have been transmitted by the International Bureau.
  - c. ☐ have not been made; however, the time limit for making such amendments has NOT expired.
  - d. ☒ have not been made and will not be made.
8. ☐ A translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)).
9. ☐ An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)).
10. ☒ A translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)).


Items 11. to 16. below concern document(s) or information included:

11. ☐ An Information Disclosure Statement under 37 CFR 1.97 and 1.98.
12. ☐ An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.
13. ☒ A **FIRST** preliminary amendment.  
☐ A **SECOND** or **SUBSEQUENT** preliminary amendment.
14. ☐ A substitute specification.
15. ☐ A change of power of attorney and/or address letter.
16. ☐ Other items or information:

"Express Mail" mailing label No.: EI 407 988 426 US

Date of Deposit: 09 July 1998 (09.07.98)

I hereby certify that this paper or fee is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" under 37 C.F.R. 1.10 on the date indicated above and is addressed to: P.O. Box PCT, Assistant Commissioner for Patents, Washington, D.C. 20231

  
Linda J. Robb

PCT/GB97/00074

WPT 0114 PUSA

17. ☒ The following fees are submitted:**BASIC NATIONAL FEE (37 CFR 1.492(a)(1)-(5)):**

Search Report has been prepared by the EPO or JPO..... \$930.00

International preliminary examination fee paid to USPTO (37 CFR 1.482)  
..... \$720.00No international preliminary examination fee paid to USPTO (37 CFR 1.482)  
but international search fee paid to USPTO (37 CFR 1.445(a)(2)).. \$790.00Neither international preliminary examination fee (37 CFR 1.482) nor  
international search fee (37 CFR 1.445(a)(2)) paid to USPTO..... \$1,070.00International preliminary examination fee paid to USPTO (37 CFR 1.482)  
and all claims satisfied provisions of PCT Article 33(2)-(4)..... \$98.00**ENTER APPROPRIATE BASIC FEE AMOUNT =**Surcharge of \$130.00 for furnishing the oath or declaration later than ☐ 20 ☒ 30  
months from the earliest claimed priority date (37 CFR 1.492(e)).

CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE
Total claims	31 -20 =	11	X \$22.00
Independent claims	9 -3 =	6	X \$80.00
MULTIPLE DEPENDENT CLAIM(S) (if applicable)			+ \$260.00

**TOTAL OF ABOVE CALCULATIONS =**Reduction by 1/2 for filing by small entity, if applicable. Verified Small Entity Statement  
must also be filed (Note 37 CFR 1.9, 1.27, 1.28).**SUBTOTAL =**Processing fee of \$130.00 for furnishing the English translation later than ☐ 20 ☐ 30  
months from the earliest claimed priority date (37 CFR 1.492(f)).**TOTAL NATIONAL FEE =**Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be  
accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40.00 per property +**TOTAL FEES ENCLOSED =**Amount to be:  
refunded \$  
charged \$

- a. ☒ A check in the amount of \$ 1,782.00 to cover the above fees is enclosed.
- b. ☐ Please charge my Deposit Account No. \_\_\_\_\_ in the amount of \$ \_\_\_\_\_ to cover the above fees.  
A duplicate copy of this sheet is enclosed.
- c. ☒ The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any  
overpayment to Deposit Account No. 02-3978. A duplicate copy of this sheet is enclosed.

**NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status.**

SEND ALL CORRESPONDENCE TO:

Mr. William G. Conger  
Brooks & Kushman P.C.  
1000 Town Center  
Twenty-Second Floor  
Southfield, Michigan 48075

SIGNATURE:

William G. Conger

NAME

31,209

REGISTRATION NUMBER

09 / 101423

Rec'd PCT/PTO 09 JUL 1998

Patent

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re application of:

PHILIP SPENCER RUDLAND et al.


Filed: Herewith

For: METASTASIS INDUCING DNA'S

Attorney Docket No. WPT 0114 PUSA

"Express Mail" Mailing Label No. EI 407 988 426 US  
Date of Deposit: 09 July 1998 (09.07.98)

I hereby certify that this paper or fee is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 C.F.R. 1.10 on the date indicated above and is addressed to the Asst. Commissioner for Patents, Box Patent Application, Washington, D.C. 20231.

  
Linda J. Robb

**PRELIMINARY AMENDMENT**

Assistant Commissioner for Patents  
Box Patent Application  
Washington, D.C. 20231

Sir:

Prior to calculating the filing fee and prior to Examination on the merits,  
kindly amend the application as follows:

**IN THE CLAIMS:**

Kindly amend claims 4, 15 and 17, and add new claims 18-31 as follows:

4. (Amended) A method as in claim 1, [2 or 3] in which the cell line that produces only benign non-metastasizing [tumours] tumors is a rat mammary epithelial cell line.

15. (Amended) A probe specific to a regulatory DNA capable of inducing metastasis as claimed in claim 7 [any of claims 7 to 13].

17. (Amended) A medicament adapted to target a regulatory DNA capable of inducing metastasis as claimed in claim 7 [any of claims 7 to 13].

18. (New) A method as in claim 2, in which the cell line that produces only benign non-metastasizing tumors is a rat mammary epithelial cell line.

19. (New) A method as in claim 3, in which the cell line that produces only benign non-metastasizing tumors is a rat mammary epithelial cell line.

20. (New) A probe specific to a regulatory DNA capable of inducing metastasis as claimed in claim 8.

21. (New) A probe specific to a regulatory DNA capable of inducing metastasis as claimed in claim 9.

22. (New) A probe specific to a regulatory DNA capable of inducing metastasis as claimed in claim 10.

23. (New) A probe specific to a regulatory DNA capable of inducing metastasis as claimed in claim 11.

24. (New) A probe specific to a regulatory DNA capable of inducing metastasis as claimed in claim 12.

25. (New) A probe specific to a regulatory DNA capable of inducing metastasis as claimed in claim 13.

26. (New) A medicament adapted to target a regulatory DNA capable of inducing metastasis as claimed in claim 8.

27. (New) A medicament adapted to target a regulatory DNA capable of inducing metastasis as claimed in claim 9.

28. (New) A medicament adapted to target a regulatory DNA capable of inducing metastasis as claimed in claim 10.

29. (New) A medicament adapted to target a regulatory DNA capable of inducing metastasis as claimed in claim 11.

30. (New) A medicament adapted to target a regulatory DNA capable of inducing metastasis as claimed in claim 12.

31. (New) A medicament adapted to target a regulatory DNA capable of inducing metastasis as claimed in claim 13.

**REMARKS**

Claims 1-31 are pending. Favorable early consideration is respectfully requested.

**William G. Conger**  
**Registration No. 31,209**  
**1000 Town Center**  
**Twenty-Second Floor**  
**Southfield, Michigan 48075**  
**Phone: (248) 358-4400**  
**Fax: (248) 358-3351**

DESCRIPTION

METASTASIS INDUCING DNA'S

The present invention relates to metastasis inducing DNA's, a method of identifying such DNA's, and their use in diagnosis and therapy.

Most cancers are thought to be due to alterations in specific genes caused either by mutation making their gene-product in some way more effective or by over expression of a normal gene giving an enhanced effect. These oncogenes have largely been identified by introducing gene-length fragments of DNA from human cancers into a mouse fibroblast cell line, in culture, and selecting those cell lines that grow in an uncontrolled manner in liquid or semi-solid medium. The oncogenes themselves have been isolated by cloning the human DNA fragments away from the mouse DNA by standard recombinatorial techniques. Alternatively mutations can arise in genes that suppress their own activity such as, for example, p53 or Rb or which suppress the levels of their products such as, for example NM-23. These are referred to as tumour suppressor oncogenes. In the commonly-occurring cancers, it is believed that between 5 and 7 such changes in oncogenes or tumour suppressor oncogenes are required to produce a full-blown cancer.

WO 86/03226 discloses a method for detecting a discrete, transmissible mammalian gene associated with tumour metastasis. The method uses a non-syngeneic

system. The teaching was later retracted - Proc Nat. Acad. Sci USA, 1988, 85 5581.

WO 94/28129 identifies a tumour metastasis gene of 2858 base pairs which codes for a protein which is expressed in malignant human tumours and their metastasis. The method used to identify it used a non-syngeneic system employing nude (defective) mice.

Cancer research 54, 2785-2793 (1994) is a paper by the applicants. It discloses a method for showing the presence of metastasis inducing DNA. No disclosure is, however, made of how to recover the sequences for identification.

Cancer research 54 832-837 (1994) is a paper suggesting that antisense OPN DNA expression was associated with reduced tumorigenicity of these cells in the flanks and in lungs. The paper does not measure or investigate metastasis as such.

EP 0607054 discloses a process for constructing a cDNA library. It described a method, using linkers and PCR for identifying signal peptides. The application is not to metastasis at all and the approach uses expression vectors for detection.

The major forms of cancer, including breast cancer, lung cancer and colonic cancer cannot be cured effectively because, although the current therapies may



-2-

be effective against the primary tumours, they are largely ineffective against the disseminating or metastasizing cells, which ultimately kill the patient. Despite the enormous effort in cancer research very little is known at the molecular level about the most important life-threatening process, that of metastasis. Most of the oncogenes and suppressor oncogenes that have been discovered have been found from their ability to promote uncontrolled growth of the mouse fibroblast cell line. The major problem in this field is that determining cell growth does not give a measure of the process of metastasis. In fact, although uncontrolled growth is an important aspect of the initial events in the development of a cancer, the rate of growth of distant metastases can be remarkably slow. Hence the process of metastasis is largely independent of processes involving cell-growth, except in its final phases. Therefore, it is unlikely that oncogenes and tumour suppressor oncogenes will have much involvement in the process of metastasis and be useful diagnostic or therapeutic targets for control and elimination of metastatic disease.

It is one object of the present invention to identify DNA comprising, consisting of or containing sequences involved in metastasis, hereinafter referred to as metastasis inducing DNA's or Met-DNA's for short.

According to a first aspect of the present

invention there is provided a method of screening and recovering a regulatory DNA capable of inducing metastasis comprising the steps of:

i. transferring tagged fragments of a human DNA from malignant, metastatic cancer cells into a cell line that produces only benign, non-metastasizing tumours when injected into a syngeneic animal;

ii. injecting the transformed cells into the syngeneic animal;

iii. selecting those animals in which metastasizing tumours have been identified; and

iv. recovering the regulatory DNA capable of inducing metastasis therefrom.

Preferably the DNA fragments transferred in step 1 are fragments of from 0.1 to 50 kilo base-pairs, more preferably 0.5 to 50 kilo base-pairs.

Preferably the cell line that produces only benign non-metastasizing tumours when injected into a syngeneic animal is a rat mammary epithelial cell line, such as, for example Rama 37.

Preferably the fragments of human DNA from malignant, metastatic cancer cells are tagged to assist in their removal or insertion from or into a host or vector, such as, for example, the oligonucleotide tag illustrated in Fig. 1. This tagging procedure overcomes the problem of identifying the inserted human DNA sequences in the rat genome of the transfected rat cells. Human-specific repetitive DNA (Alu) sequences are spaced sufficiently in the human genome that in many human DNA

-4-

fragments of this size they will be absent.

In one embodiment, fragments of human DNA from malignant, metastatic breast cancer cells are introduced into a rat mammary epithelial cell line Rama 37 which produces only benign, nonmetastasizing tumours when injected into syngeneic rats.

By way of example only, the transfer of restriction-enzyme *HindIII*-fragmented DNA from malignant metastatic rat and human breast cancer cell lines into a benign Rama 37 cell line produced a small proportion (1-3%) of transformants which, when reintroduced into the syngeneic rats, caused these cells to metastasise, principally to the local lymph nodes and lungs. In contrast, fragmented DNA from nonmetastatic cells and the standard oncogenes (Ha-ras, Middle T Antigen gene, and Large T Antigen gene) produced no metastasizing transformants. The latter result confirms the non involvement of such oncogenes in the metastatic process *per se*. However, the fact that metastasis can be transferred in a genetically dominant manner suggests that other dominantly-acting DNA fragments are largely responsible for this process. The full results of the above experiments are shown in table 1, which shows the incidence of tumours and metastases for Rama 37 transfected cell lines.

The column headed "cells injected" gives the cell type in short hand, and full details are given

-5-

below:

Rama 37 are Rat mammary 37 benign cells; R37-Ca2-LT1 is a cell line from a lung metastasis of Rama 37 cells transfected with fragmented DNA from the metastatic breast carcinoma cell line Ca2-83 (Cancer Res 54 2785-2795, 1994); B-T1 is a cell line from a primary tumour of Rama 37 cells transfected with fragmented DNA from the benign breast cell line HMT-3522 (Cancer Res. 54 2785-2795, 1994); R37-Ca2-HT is a cell line of Rama 37 cells transfected with tagged DNA fragments from metastatic transformant R37-Ca2-LT1; R37-Ca2-H is a cell line of Rama 37 cells transfected with untagged DNA fragments from metastatic transformant R37-Ca2-LT1; R37-B-HT is a cell line of Rama 37 cells transfected with tagged DNA fragments from the benign transformant B-T1 as a control; R37-F1 is a cell line of Rama 37 transfected with PCR fragment F1 from a cell line of a lung metastasis of R37-Ca2-HT; and R37-F2 is a cell line of Rama 37 transfected with PCR fragment F2 from the same cell line of a lung metastasis of R37-Ca2-HT.

The b annotation in the column headed metastases identifies the transfecting DNA's giving rise to significantly more metastasis than Rama 37 cells ( $P < 0.05$ , Fisher exact test). The animals were autopsied after 3 months.

To aid the rescue of metastasis-inducing human DNA sequences from the rat transformant cell lines, all

-6-

the HindIII-fragmented DNA's from one such metastatic transformant, R37-Ca2-LT1 (Table 1) were tagged at both ends with double-stranded synthetic oligonucleotides that provide restriction enzyme and unique PCR primer sites. These are shown in Fig. 1. The tagged DNA fragments include 4 restriction sites: *Sfi*I and *Not*I, a defective *Hind*III site at the 3' end for linking to the *Hind*III sites at the ends of the human DNA fragments, thereby destroying it, and an internal *Hind*III site located near to the 5' end, which when cut after ligation generated new fragments with *Hind*III ends. The fragments were transfected into the parental Rama 37 cells, and after transfer of the cells to the mammary glands of syngeneic rats, metastatic cell lines were isolated from the resultant rat lung metastases. The tagged, fragmented DNA incorporated into the metastatic transfected Rama 37 cell lines was directly amplified between the tags by PCR and yielded bands at about 1300 to 1500 bp that were responsible for the metastasizing ability of the transfected cells. These results are shown in Fig. 2 which shows the DNA fragments produced by PCR of metastatic transformants. Two new cell lines, established from the culture of lung metastases of R37-Ca2-HT (tagged, metastatic DNA transformant) and R37-Ca2-H (untagged, metastatic DNA transformant) (see Table 1) in rats were termed HTLu and HLu, respectively. They were run against the tagged benign transformant cell

-7-

line R37-B-HT and the tagged metastatic transformant R37-Ca2HT. Cellular DNA was amplified by PCR using a short oligonucleotide primer of 22 bp from positions 3-24 of the tag sequence as shown in Fig. 1. Compared with the control DNA's from HLu and B-HT cells, two extra bands, F1 and F2, of about 1300 bp and 1500 bp respectively, were specifically amplified from genomic DNA of the Ca2-HT and HTLu cells when PCR'd DNA samples were run on 0.8% agarose gels containing ethidium bromide and photographed in U.V. light. The fluorescent bands of DNA are shown in negative imaging for clarity. Cloning of these pooled DNA's yielded six independent fragments and the results are illustrated in Fig. 3. Fig. 3 shows pBluescript clones of metastatic DNA fragments F1 plus F2. The two broad PCR DNA fragments F1 and F2 were excised from the gel in Fig. 2, combined, and cloned directly using the AT procedure into a suitably modified pBluescript vector and the clones of recombinant vectors were cut with *HindIII* to excise the cloned fragments. These cut recombinant vectors were analysed on a 0.8% agarose gel containing ethidium bromide and photographed in U.V. light. The sequences of some clones eg. C10 and C9-DNA's were identical; the six independent sequences arose from clones numbered C2, C5, C6, C9, C12 and C20 and hence are referred to as C2-DNA, C5-DNA etc as shown in Fig. 3. The position of the vector (Vec) DNA and insert (Ins) DNA are indicated and a standard molecular weight

-8-

ladder in kilobase pairs (kbp) is shown in lane M. Transfection of these cloned DNA fragments singly into the parental benign cell line confirmed that all fragments (C2, C5, C6, C9, C12 and C20-DNA's) produce metastases. These are shown in Table 2 which tabulates the incidence of tumours and metastases for Rama 37 cells transfected with cloned Met-DNA's. The superscript a - e indicate:

<sup>a</sup>Benign nonmetastatic Rama 37 cells were transfected with pSVneo or with pSV2neo and different independently-cloned inserts of the pBluescript library of pooled F1- and F2-DNAs termed C2-DNA etc. or with a cyclomegalovirus expression vector pBKCMV (CMV-1) or with the CDNA for osteopontin (*opn*) cloned into the same expression vector pBKCMV*opn* (OPN-1).

<sup>b</sup>Transfectants were tested for their level of *opn* mRNA relative to that in Rama 37 cells by Northern hybridisations to *opn* CDNA using a Shimadzu CS9000 scanning densitomer. RNA loading levels were standardised with respect to a 36B4 ribosomal protein constitutive probe.

<sup>c</sup>Transfectants were tested in the mammary glands of rats for the percentage (%) of tumour-bearing animals with metastases in the lungs after 3 months. The incidence of tumours produced by all transfectants was 100%.

<sup>d</sup>Significantly higher levels than for Rama 37

-9-

cells ( $P < 0.05$ ; Mann Whitney U test).

<sup>e</sup>Significantly more metastases than for Rama 37 cells ( $P < 0.05$ ; Fisher exact test).

Thus Koch's postulate has been satisfied for all metastasis-inducing-DNA's (Met-DNA's) in this system.

Southern hybridisations and PCR amplifications have established that the Met-DNA's are specifically present in their respective transformants.

Fig. 4 shows detection of C9-DNA in transformant cell lines. Cellular DNA was isolated from (A) a cell line from a lung metastasis produced by injection of C9-DNA transfected Rama 37 cells in rats; (B) C9-DNA transfected Rama 37 cells (see Fig. 3 and Table 2); (C) benign Rama 37 cells; (D) benign BT-1 cells (see Table 1). These DNA's were digested with *Hind*III and the digested DNA was analysed on 0.8% agarose gels either by (A) Southern blotting to a probe of [<sup>32</sup>P] radioactively labelled C9-DNA, and the radioactivity visualised on X-ray film or (B) by PCR using the 17 oligonucleotide fragment from either end of the C9-DNA as primers and run with a standard molecular weight marker ladder. The newly synthesised DNA in B is visualised by fluorescence of the ethidium bromide in the gel in U.V. light.

Surprisingly, the sequences of these Met-DNA's (sequence 1 to 6 hereafter), although human in origin, do not correspond to known genes and most do not include any



-10-

known open reading frames. Furthermore none of these Met-DNA's are expressed as mRNAs in their transformants and hence are not dominantly-acting oncogenes. They therefore contain entirely novel short stretches of regulatory DNA capable of inducing metastasis.

The state of the Met-DNA's has been investigated in the metastasizing transformant cells. Bands of greater than 23kbp which hybridise to the C9-DNA probe have been obtained from *Hind*III digested C9-DNA transformants, and pulsed-field gel electrophoresis yields multiple bands of about 16-48kbp after similar digestions as shown in Figure 5a-d.

Fig. 5 shows the detection of Met-DNA in transformant cells. The cellular DNA was isolated from : (A) a cell line from a lung metastasis produced by injection into rats of C9-DNA transfected Rama 37 cells; (B) C9-DNA transfected Rama 37 cells; (C) benign Rama 37 cells; (D) benign primary tumours of R37-BT-1 cells. These DNAs were digested with excess *Hind*III and the digested DNA was analysed on agarose gel (a) with continuous electric field; (b) with a pulsed electric field; or (c) by PCR using 17 mer oligonucleotide primers from each end of the C9-DNA; (d) These DNAs were also digested with excess *Eco*R1 and analysed on agarose gels with a continuous electric field. The resultant gels were either (a.b.d) Southern blotted to a probe of [<sup>32</sup>P] C9-DNA without tags and the radioactivity visualised on

-11-

X-ray film or (c) the newly synthesized DNA was visualised by fluorescence of the bound ethidium bromide in U.V. light. Controls with (a) C9 DNA in lane P and (c) standard molecular weight marker ladder in kilobase pairs (kbp) in lane M were also run. This result strongly suggests that the flanking *HindIII* sites have been destroyed by the transfection/integration process. The highest 48kbp band is preferentially retained by the cell line isolated from a lung metastasis (Figure 5b); thus it is likely that this represents most of the metastasis-inducing DNA (Table 2). The C9-DNA transfectants contain about 100 copies per haploid genome of C9-DNA when compared with a single copy (Figure 5a, lane P) 10 copy and a 100 copy DNA control. PCR amplification of the integrated DNA using primers complementary to the cDNA adjacent to the untagged ends of C9-DNA produces a single 1kbp product showing that the integrity between the primer sites has been maintained (Figure 5c). However, digestion of the DNA of C9-DNA transfectants with *EcoRI* (which cuts once internally within the C9-DNA) and hybridisation with a C9-DNA specific probe yields predominantly a 1kbp band of similar size to the original C9-DNA insert (Figure 5d). This 1kbp band probably arises from the digestion of tandem repeats of C9-DNA. Similar results have been obtained with C2, C5, C6, C12 and C20-DNAs.

The occurrence of C9-DNA has been investigated

in pilot studies in the DNA of human breast cancers. Hybridisation of C9-DNA occurs to *Hind*III-digested DNA from 4 out of the 9 breast tumours tested, whereas no hybridisation signal is detected from similarly-digested DNA from normal human breast or colon tissue. In this case a single hybridising band of 1000bp is detected (Figure 6).

Figure 6 illustrates detection of C9-DNA in human breast tumours. Cellular DNA was isolated from a selection of nine randomly-picked human breast tumours numbered 14-130 and from normal breast and colon tissue together with C9-DNA as a control. These DNAs were digested with an excess of *Hind*III and the digested DNA was analysed on agarose gels, Southern blotted on to a filter and hybridised to a probe of [<sup>32</sup>P]C9-DNA without tags and the radioactivity visualised on X-ray film. Similar results have been obtained using PCR for C9-DNA.

According to a second aspect of the present invention there is provided a regulatory DNA capable of inducing metastasis consisting essentially of a human DNA fragment of less than 1.6 kilobase pair in length obtained from a malignant, metastasis cancer cell.

According to a third aspect of the present invention there are provided DNA consisting essentially of a regulatory DNA capable of inducing metastasis from sequence 1:

C2

CTTCCTTGGT GCTCTATGTC TTGCCTCTCC CCTTCTCCAG TCCCATTAAG CCATAACCAT  
CTTGACAGAC TCTGGGACAG TCCCCTCTGC TCTCCTGTTG GCGCCTGAGT CCCTTTTTTG  
CTGAGGACCC TTCACGTAGC CTCCCATCTG GATGACCTAG TAGAAGACGT GGGAAAGTTGT  
CACACTCAGG TAACTGAGCA GAGCTCAGAG ATTTAAAGTG AGTCTGGGGA GCCTCGAGGA  
TTGATCTGCT GCCTTAAAAA GCCAATTGGA TGACTAACCC AGACTATTGT CACTTTAGGT  
GGGAAGTCAC TAGCATATCT GATGGGTCAC ATCTGAGAAA GGTTCCTAGC AGTGGTGGCC  
TTGTGTGAGC AGCATGGCGT GTATCATGGT GTGCAGCATA CTCAGGCTGC TTGCAACACT  
CGAGGCTCTT CTTCAGTATT AGGGGAACCA CTGGTGTTSG AACATGGTCC AAGAATACAG  
TCATGTGAGG AGAATCCCAA TGGGTCAGGA GAAAACGAGA GTCTGTGACC TCCATTCTTC  
AAGATACAGA APTATTCTTG GACTGTGTTT TCATGCTCCT TGTGGATGGG AGTGAGTTTA  
CTTCAGGTTA ATCAGCATTG CTTACTGTTG GTATTCAAGT AAATGCTTAA ATTATCCTGG  
ATATACCTCT GTGGGAAGCA GGTTCCTGAT ACATGCAGCT TGTCTTGTG ATTGATACTG  
CTTGAACTCA AGAGAACTTT GCTCATGTGA TCTTTCTTAA CCGATGGAGT AGAAACTGTC  
TGATGCTCTC AATAAAGTTG GCTCTTGAC GAGACGTTAG TCTGTCTGT TTATCTGCTC  
CATTCTTCCG CTCCCACGGC CTCTACAGCA CTAAACCCAC CACCGATAGA CTCAGTCTTT  
CACTGACAAA CATCACCA GAAGCTCTTAA TGAGATTATA AACTGTTACT AGATGATGGG  
TGGATCGCT CCCCAGAAAC ATAAACATTT ACTTGGAGAA CTCAAGACCC CTTTGTAGAC  
ATAACTCCCA TGGT

According to a fourth aspect of the present invention there are provided DNA consisting essentially of a regulatory DNA capable of inducing metastasis from sequence 2:

C5

ATTGCTGTGA GCCTATTAGC GACATTTGGT GACGCCCCCTT TTAAGGGGGT AGATACAAAG  
AATGGGTTGA AATTCTGTGC CACAAACGCT CTCCATGTTT TCACAATTAC ACTTGCAACC  
TGTGGTCAGC AGCCAGAAAT TAGGGATGTG ATGGGACAGG GTCCGGGAAA GAAGGAGAAG  
GGTAAAGGAA AGACAGCACC TTAAGTCCA AACAGCTCCA GGAGACTATC TGTAAGAAATA  
ACATCAGACC ATGAGGAGAA TTGATATCAT TGTTCCTCAA TGGGTATCGC CAAGGGAACT  
TTCCATCTGA TTAATAATA TTAATGCTCG CACTAAATCC AATTGGAAAT GCCCCACACA  
ATTTATCTTC CACTTCATGC TGCTACCAAT TGCCTGACGT GCGGAGCAG AAGCAATCCC  
TCCCGTTCTG ATAAATAGTA CTTTGTAAT ATTTGGAGAC GGGAGCTCTG GTGACAGGGA  
ACACGTACAA ACCGGCCTGT TATCAATGT CCCGATAGAG GCCCTCTTTG ACGTACAGGA  
CCCCAAAACA GTCAGGATGC TGTGAATTT CTTCCATGAA GCCTTGTTCA CAATTAGCAA  
CCATTGGAGG AAGCAGGCTG CACTGTCTAC CACAAGTGGC ACTTTCCAAA GAGCACACAT  
ATATTGGAGC AAGACATTTT CCTGGCTGAC TGGTGCTGTG TAAGCTGATA AACTGCTATA  
TTTATTAAAC TGGCTTTTCT TTGAACACCC CACTCAAGGA AAAAAAACA CACTTAGGGT  
GACATTATTT GGAGATGAAG TCTTTATAGA GATGCTTAAG TTTAAACGAG ACTTTTAAAG  
CCGGCTCTAT TCCATTTAAT GAATGGTGTC CCTACAAAGG AAGAAACTGG GACAGAGGTA  
TGTACACTTG TGTGTGTGTG AGAGACAACG TGAGGAGCTG AAGAGGAGCA CGTACAAGTC  
AGAGAAAGGC TGACCCCTTAT TCACACTGAG CAAACCAAGT ATGTGTGGGT CGATAGATGA  
GAGTATCCCC CAAGACTCAC ACATTGCAAC GCTTGGTC

AMENDED SHEET

According to a fifth aspect of the present invention there are provided DNA consisting essentially of a regulatory DNA capable of inducing metastasis from sequence 3:

C5

AGGACCAGAG TTCACATCCC ATCAAATGGC CCAGAAGGTT TTAATGCTGT CTTTTGGCCC  
ACGGCCGAAC TGCACACACA TGTGCACATA CACTTACAGA GACACACATT CAGCAGCATA  
AGAACACAAT CACAAATAAA AAAAATCTTG AAAAATTTTA AGCTAAAATT GTTAAGAAAT  
AACATATATA CAATTTTCTT TTATTTTCTT AAAGATTTAT TTATTTAATG TATATGAGTA  
CACTGCCTCT CCCTCCAGAC ATAGCAGTAC AGGGCATCGG ATCCCATTAC AGATGGTTGT  
GAGCCACCAT GTGGTTTTCAC AGATGGTTGT GAGCCACCAT GTGGTTTTCAG GAATTGAACT  
CAGGACCTTT GGAAGAGCAG TCAGTGCTCT TAACCTCTAA GCCATCTCTC CTGACCCTTA  
TATACAATTT TAATGCTACG TACACACAAC TTCTCTTTCC TTAAATGGTT GAGATTTTTC  
TCTGGAGAAG TAAGAATAAA GGAGGGAAAG AACATTGCTT TCACATTGCA CCAGTGGGAA  
CAGCGTGTTC AAAGTAGGAA TGCCATGAAA TGACTGGCCT GCCTTCTCAT TACTGTTCCCT  
CCCCTCCTC CTTTTAACTG GAGCTCCTTT ATCTAATTTA TTAGTTTGAC GATACCCAGG  
GTTTTCTTCT GTTTTGATCT TTTTAAGACA GAGACTCACC ATATAGCCCT GGCTGGCCTG  
AAGCTCACTA TGTAGACCAG TCTGGCCTTG AACTCAAAGG AGATCTATCT GCTTCCTAGT  
GCTGGGATTA AAGGCTTGTC CTACCAAGTC TGGTCTGAGG CTTTGGAGCA GCCTCGGTTT  
TGGCCTTCTT TAAGGATCTC TAAGCTAGCA GTAAGTAGCC TAGCCATGCT GTTGTAGGAA  
GTTGTTGCTT CATCCTGGCT CCAGCACAAA GGCAGTCACT AAACGTGGG CTCAATTCAT  
CAGAGCTGAA TGCRAATTC TTGTGCTCTT CCTGTGTCTT CCTGGAAC

According to a sixth aspect of the present invention there are provided DNA consisting essentially of a regulatory DNA capable of inducing metastasis from sequence 4:

C9

AGTTGGGGAC ACAGCTTGCT TGATTAGAT GTTCTCTGGG AAAAGGAGTT AAGCCTAATG  
ATTTCCRAATG GAAAGGACTG CTAATTGGGG AGGCAATGTT GCTTAATTGG GACACCTGCG  
GGTAATTAAA AGCTCTCTCC CAGTGGCCTT TCCTGTTTTT GGCTCTGGGA GGCGAAGGCA  
TTGAGAGGGA TGCAGGCATT CTAAGGGCTG GTTCTTGGIT TCTCCCTTCC CCTCTGTCCA  
AACTCAGTGA GGTATCCCTG TCTGTGCTGT CCTTAGAGTG CCGTCCCTGAG GCCTTGGTGA  
GTTAAGGTCT CTGGATCTGA GCTGCCTCAG GGAACCGCAT GAGCTCATTG GAAAGGGGAG  
AACCAGGCAA AGGTGTTGGC TGTGACCTCA GAATTCTGAG GGGCAAAGGT TCAAGGCTAA  
CTCTCATTAT AGAGCAAGTT TGAGACTGGC CTGGGAACAA AATATTAAG TGAGTGAGGT  
CATATGACAG CACCTGAGGA GTCCTGTCCC TAGAGATCAT AAGGACCTGG CTGCTGGGGA  
CTTGTTGCAG ATGGCACTTT GTGTGAGAG AGGGGACCTG CCCCAGCATG GGAGGCCCTG  
GAAGATCCTC TGGATTAACT GTGAACACTG ATTGCTGCTT TATACCTGGA GTTGTGCTGT  
TATCTGGTAC ACATCTGCTG GGTGAATGAG TTCATGGGCT TTATTTCACT GAGGTATTTA  
CCTGAGGAGA AAGAAGGACT GGTGCCACAA AGCACAGCTT TTAATCTGT GGGTTGTGAC  
CCATTATGGA CTATCATAAC TGAGTGACAG TATCAAGAT ACTTTAGCAG GTGGTAAAAA  
GATTTTTGAA TCGGCAACGA CCAAACTGA ACTCAAAAAT CAAGCATGGC ATGGATCCTG  
GGTGCTCCTG GAAGCACTTG CTTTACTGC ATTGTGCGAC TTGACGGTAG CCTTGCTTCT  
GAATGCACAA CACGTGGGCT TTGGGCTGCA CAGGCCACCA CGCCGTGCCT GAAACACCTC  
AGCTCAGGTT TGTGGCTATG TCCTATGACT TGGACTTACT TTTATTGCAC ATATAAATAT  
TTTCCTGC

According to a seventh aspect of the present invention there are provided DNA consisting essentially of a regulatory DNA capable of inducing metastasis from sequence 5:

C12

GAGGGGGTGG	TGGCACAGTT	ATGTTTTTGT	AGGAAGGGTT	CCATGAACCT	CAGCAGAGCT
CGGGTTAGAA	ATTTAAAAGC	CCTGAGGGGA	ATTTTTTTTT	TRAATCGCTA	TGAATCTGAC
ATGAGAAAAA	CAGATCAGAA	ACGTTCTTGT	GCTTCAGAAA	AGGACAGTG	TGTGAGCTAA
CAGACTGCAC	ACTGGTGTTT	GAGGCACATC	TGGATCACAG	GAGCGTCAGA	TAATGTCCCC
AAAGGTAAAT	GCATTTGCTT	GCACAGTACC	GAGTGTGGTG	GGGGGTGCCT	ACAGCCCAGC
GGTTCTCAAC	CTTCCTGATG	CTTCGACCCT	TTAATACAGT	GCCTCATGCT	CTGGTGACCT
CCCCAACCTT	AAAATTATTT	TTGTTGCTGT	TCATAACTGT	GATTTTGATA	CTGTTATGAA
TTGTAATATA	AATAATTTTG	AAGAAAGAGG	TTTGCCAAGG	GTTTGAGAAC	TGCTGTTCTA
GCCCCACGTG	GATGGTTTTT	CGTCATTTGG	GGTTTTTTATG	AGGCAGAGTC	TTATGTAGCC
CAGGCTAGCA	GCCTAGAATG	TGCTACTTAG	CTGAGGAATA	ACCTTGGAAC	TTCTGAGGAC
TGGAGAGACT	GGCTTAGTCC	TCAAGAAACT	GGAATATAGCT	GGAGTTTGCC	TACTTGTGGG
TTCCTTTTTC	TTCAAACCTT	TTCTACTCTT	TTTCCACCCT	GTCGGCCCCC	TAACACTAAA
TAAGAAAGAG	AAAGGGGAGC	ATAGAGGGGA	AAAGAAACCC	CTGAATAACG	TCAGTAGTTG
GCAAGGGGGG	GTGACATATG	TTGTCATTAG	ACCACATCCT	GGTGATTAAAG	GGGAGTCAAG
TTCCTTGGGG	CAAGTTTGAT	CTTTCGTGTA	ACGATATCTA	ATTTCTTCTC	CCTGTTGCTT
CGTCCTTGTC	AACAACGACT	TGATAACCCA	CAATGGACCA	TCAACCAACC	AACCAACCAT

According to a eighth aspect of the present invention there are provided DNA consisting essentially of a regulatory DNA capable of inducing metastasis from sequence 6:

C20

TTGCTCTCTGG TGTACTTTGT TTTCCCAATT CTGACAGTGG TTTGACCTT CTATACGCCT  
GTGTGTCAGG AGTGCTGTAG ACCTATTTTC CTGTTTTCTT TCAGCCAGTT ACAGGAACAG  
AGTGTTCTAC TGTGAGATGT GTAGCTGTTC CTGTCCACTG ACTTTCAAGC TGTCTCTGTG  
TGCAGGAACC AGAAGGGCCT GTCCCTACTT CTACTGGGCC CCTACGCACA GGGGGCCTAG  
ATGGTGCTAG GTGTTTTTCT CTAGAGCCTG AAATGTGGGC AGAGAGTAGT CTCCTCTGGT  
TTCCTAGGTA TGTCTTCCCC TCTGAAGGTC TAGCTCTCCC TTCCATGGGA TATGGGTGCA  
GGGAGCTGTT TGACCAGGTC CTCTCAATC CGGGTGCAGT CTGGACCGCA GGCTCCTGTA  
GCTTGCCCTGC TGCAATCTTC CCGCACCCAG AGGCACCCAA GTTTCCTCTT GGGCCAGGA  
TGTGGGCAAA GGTGGGCAGA AGTGGCAATC TCTCCTGCCC TAGCGTCTCA GGATTGCCCT  
CACTTCTGGG CAATCCGCTC TCTCTTCCAC AGGGTTTGGG AGCAGGGAGC TGTGGGCCGG  
TATCAGGCAA AGGTTTGAGG CAACCAGTGA GAAACTGGAA GTGTGAGGTC CCAGAGGAAT  
TTTGCCCTTTG TGTGTCCTGA GTCCACCAGG CAGGTCACCT GGAGCAGAAA AATTGGTTTTT  
CCCCTCGGTC TCAGGCCTGA AGTTCACCT CAGGGTTGGC TTTCAGCTGT ACCTGTGGAA  
AGTATGGITT TAAAAATCTA AGATAGCTAT CATGCAGCAA GGCTTGTGTA AAATGTCTAT  
TTGGTTCCTT TATGACTTAC TTTTGCTGTA CTGAGGATCA AACCTAGGGT CTCAGCAGT  
CATCACAATT CTCTGTCACT GATCCAGCTC CATTTCTATT TTCTTTTGTG CCGCGCGATC  
TCTCGGCAGC- AAGAAAACAC GCTAGGGACA TACGAATCCT TGCTGCAGCC AAAACTTTTA  
TTGAATCTTA AGGAGAAGCC CGCGCACCGG ACTGGCGCGG TTTATATACA CCCTAGCACA  
CTGCATCCAC A

Detailed examination of their DNA sequences has confirmed that the six Met-DNA's bear little relationship to one another. C6-DNA shows 86% homology to 102 bp of the rat WAP promoter (Nucleic Acids Res. 12 8685-8697 1984) with a novel duplication of 30 nucleotides of this region. All Met-DNAs contain recognition sequences for transcription factors TCF-1 (EMBO J. 10. 123-132, 1991) and HIP1b (Mol.cell. Biol. 10, 653-661, 1990). Moreover all but one contain recognition sequences for CTCF (Oncogene 5, 1743-1753, 1990), HIPlA (Mol.Cell.Biol.10, 653-661, 1990), NF-1L6 (EMBO J. 9 457-465, 1990) and regions of potential Z-DNA (Nature 282, 680-686, 1979),

AMENDED SHEET



with C6-DNA containing a tract of 23 alternating purine-pyrimidine bases. Thus these novel sequences all contain potential regulatory regions for transcription of DNA into mRNA but no known coding or viral-related sequences.

According to an ninth aspect of the present invention there is provided the use of an osteopontin gene as a metastasis inducing transformant.

In one embodiment Met-DNA's, are introduced into a benign rat mammary epithelial cell line Rama 37.

By way of example and to help identify the regulatory function that short stretches of human malignant DNA (precursor to Met-DNA's) may exert on the transfected Rama 37 cells, the mRNA expression of the metastatic transformant rat mammary cell line R37-Ca2-LT1 was compared with its benign parental cell line Rama 37 using subtractive hybridisation techniques. Of the four subtracted clones three corresponded to known rat genes for proteins including osteopontin and one corresponded to a novel rat gene of unknown function. As an example only, transfection of rat osteopontin cDNA into the parental Rama 37 cells produced transformants that induced a high frequency of metastasis compared with vector controls confirming the metastatic capability of



-18-

the osteopontin gene as shown in Table 2.

These overall results have established a causal relationship between the Met-DNA's and metastasis on the one hand and the over-or underexpression of certain rat genes, at least one of which is novel, that are linked to the metastatic process in this rat system. Controls with DNA's from nonmalignant, nonmetastatic sources as well as the oncogenes Ha-ras-1, Polyoma Large T Antigen and Polyoma Middle T Antigen failed to induce metastasis establishing the specificity of the inductive processes in this system.

At present the most useful indication of whether a breast or other common cancer will metastasise in the future in a patient is whether the primary tumour has already spread to the local lymph nodes. This test only works on a population basis. For example, in breast cancer, there are many examples of patients with no tumour in the lymph nodes at presentation who later die of metastatic disease and of patients with metastatic deposits in the lymph nodes who live a normal life-span. Thus an accurate test of good predictive value for the occurrence of metastases would be important in selecting those patients for vigorous conventional chemotherapeutic treatments without causing the potentially harmful side-effects in those patients who do not need this treatment.

According to a tenth aspect of the present

invention there is provided a probe specific to a regulatory DNA capable of inducing metastasis.

By specific is meant hybridises to any target DNA under suitable salt and temperature conditions to allow detection of identical or related DNA molecules.

Preferably the probe is provided as part of a kit which may additionally comprise one or more of the following: a colour indicator; an oligonucleotide primer; materials for gel analysis, and/or materials for DNA transfer or hybridisation.

The Met-DNA sequences may be detected in tumour or biopsy specimens by standard Southern blotting, PCR-based or in-situ techniques to identify those patients at risk from metastatic disease. Physical methods of detection based on imaging techniques may also be possible. Expression of metastasis - inducing genes may be detected by standard mRNA hybridisation PCR amplification or by antibodies specific for the gene-product.

According to a eleventh aspect of the present invention there is provided a medicament adapted to target a regulatory DNA capable of inducing metastasis as claimed in any of claims 7 to 13.

In one embodiment such Met-DNA's, metastasis-inducing genes or fragments thereof, could be

-20-

targeted in the cancer cells to excise or block their function using synthetic oligonucleotides based on a knowledge of the sequence of the Met-DNA's, metastasis-inducing genes or fragments thereof, of the invention.

In another embodiment such Met-DNA's, metastasis-inducing genes or fragments thereof, may be targeted for treatment using standard antibody and antisense mRNA/ribozyme techniques for detection and for destruction, respectively.

## Sequence 1

CTTCCTTGGT	GCTCTATGTC	TTGCCTCTCC	CCTTCTCQAG	TCCCATTAAAG	CCATAACCAT
CTTGACAGAC	TCTGGGACAG	TCCCCCTCTGC	TCTCCTGTTG	GCGCCTGAGT	CCCTTTTTTGC
CTGAGGACCC	TTCACGTAGC	CTCCCATCTG	GATGACCTAG	TAGAAGACGT	GGGAAGTTGT
CACACTCAGG	TAACTGAGCA	GAGCTCAGAG	ATTTAAAGTG	AGTCTGGGGA	GCCTCGAGGA
TTGATCTGCT	GCCTTAAAAA	GCCAATTGGA	TGACTAACCC	AGACTATTGT	CACTTTAGGT
GGGAAGTCAC	TAGCATATCT	GATGGGTCAC	ATCTGAGAAA	GGTTTCTAGC	AGTGGTGGCC
TTGTGTGAGC	AGCATGGCGT	GTATCATGGT	GTGCAGCATA	CTCAGGCTGC	TTGCAACACT
CGAGGCTCTT	CTTCAGTATT	AGGGGAACCA	CTGGTGTTSG	AACATGGTCC	AAGAATACAG
TCATGTGAGG	AGAATCCCAA	TGCGTCAGGA	GAAAACGAGA	GTCTGTGACC	TCCATTCTTC
AAGATACAGA	AFTATTCTTG	GACTGTGTTT	TCATGCTCCT	TGTGGATGGG	AGTGAGTTTA
CTTCAGGTTA	ATCAGCATTG	CTTACTGTTG	GTATTCAAGT	AAATGCTTAA	ATTATCCTGG
ATATACCTCT	GTGGGAAGCA	GGTTTTTGAT	ACATGCAGCT	TGTCCTTGTG	ATTGATACTG
CTTGA ACTCA	AGAGAACTTT	GCTCATGTGA	TCTTTCTTAA	CCGATGGAGT	AGAAACTGTC
TGATGCTCTC	AATAAAGTTG	GCTCTTGCAC	GAGACGTTAG	TCTGTCTGTG	TTATCTGCTC
CATTCTTCCG	CTCCCACGGC	CTCTACAGCA	CTAAACCCAC	CACCGATAGA	CTCAGTCTTT
CACTGACAAA	CATCACCAGA	GGCTCTTAAC	TGAGATTATA	AACTGTTACT	AGATGATGGG
TGGAATCGCT	CCCCAGAAAC	ATAAACATTT	ACTTGGAGAA	CTCAAGACCC	CTTTGTAGAC
ATAACTCCCA	TGGT				

ATTGCTGTGA	GCCTATTAGC	GACATTTGGT	GACGCCCCCTT	TTAAGGGGGT	AGATACAAAG
AATGGGTTGA	AATTCTGTGC	CACAAACGCT	CTCCATGTTT	TCACAATTAC	ACTTGCAACC
TGTGGTCAGC	AGCCAGAATT	TAGGGATGTG	ATGGGACAGG	GTCGGGGAAA	GAAGGAGAAG
GGTAAAGGAA	AGACAGCACG	TTAAAGTCCA	AACAGCTCCA	GGAGACTATC	TGTAGAAATA
ACATCAGACC	ATGAGGAGAA	TTGATATCAT	TGTTTTTCAA	TGGGTATCGC	CAAGGGA ACT
TTCCATCTGA	TTAAAAATAA	TTACTGCTGG	CACTAAATCC	AATTGGAAAT	GCCCCACACA
ATTTATCTTC	CACTTCATGC	TGCTACCATA	TGCCTGACGT	GGCGGAGCAG	AAGCATTCCC
TCCCGTTCTG	ATAAATAGTA	CTTTGTAAAT	ATTTGGAGAC	GGGAGCTCTG	GTGACAGGGA
ACACGTACAA	ACCGGCCTGT	TTATCATGTT	CCCGATAGAG	GCCCTCTTTG	ACGTACAGGA
CCCCAAAACA	GTCAGGATGC	TGTGAATTTT	CTTCCATGAA	GCCTTGTTCA	CAATTAGCAA
CCATTGGAGG	AAGCAGGCTG	CACTGTCTAC	CACAAGTGGC	ACTTTCCAAA	GAGCACACAT
ATATTGGAGC	AAGACATTTT	GCTGGCTGAC	TGGTGCTGTG	TAAGCTGATA	AACTGCTATA
TTTATTAAAC	TGGCTTTTCT	TTGAACACCC	CACTCAAGGA	AAAAAAAACA	CACTTAGGGT
GACATTATTT	GGAGATGAAG	TCTTTTATAGA	GATGCTTAAG	TTTAAACGAG	ACTTTTAAAG
CCGGCTCTAT	TCCATTTAAT	GAATGGTGTC	CCTACAAAGG	AAGAACTGG	GACAGAGGTA
TGTACACTTG	TGTGTGTGTG	AGAGACAACG	TGAGGAGCTG	AAGAGGAGCA	CGTACAAGTC
AGAGAAAGGC	TGACCCTTAT	TCACACTGAG	CAAACCAGTC	ATGTGTGGGT	CGATAGATGA
GAGTATCCCC	CAAGACTCAC	ACATTCGAAC	GCTTGGTC		

- 22 -

## Sequence 3

AGGACCAGAG TTCACATCCC ATCAAATGGC CCAGAAGGTT TTAATGCTGT CTTTTGGCCC  
AGGGGCGAAC TGCACACACA TGTGCACATA CACTTACAGA GACACACATT CAGCAGCATA  
AGAACACAAT CACAAATAAA AAAAAATCTTG AAAAAATTTTA AGCTAAAATT GTTAAGAAAT  
AACATATATA CAATTTTTCT TTATTTTTTT AAAGATTTAT TTATTTAATG TATATGAGTA  
CACTGCCTCT CCCTCCAGAC ATAGCAGTAC AGGGCATCGG ATCCCATTAC AGATGGTTGT  
GAGCCACCAT GTGGTTTCAC AGATGGTTGT GAGCCACCAT GTGGTTTCAG GAATTGAACT  
CAGGACCTTT GGAAGAGCAG TCAGTGCTCT TAACCTCTAA GCCATCTCTC CTGACCCTTA  
TATACAATTT TAATGCTACG TACACACAAC TTCTCTTTCC TTAAATGGTT GAGATTTTTG  
TCTGGAGAAG TAAGAATAAA GGAGGGAAAG AACATTGCTT TCACATTGCA CCAGTGGGAA  
CAGCGTGTTT AAAGTAGGAA TGCCATGAAA TGACTGGCCT GCCTTCTCAT TACTGTTCTT  
CCCCTCCTC CTTTTAACTG GAGCTCCTTT ATCTAATTTA TTAGTTTGAC GATACCCAGG  
GTTTTCTTCT GTTTTGATCT TTTTAAGACA GAGACTCACC ATATAGCCCT GGCTGGCCTG  
AAGCTCACTA TGTAAGACCAG TCTGGCCTTG AACTCAAAGG AGATCTATCT GCTTCCTAGT  
GCTGGGATTA AAGGCTTGTT CTACCAAGTC TGGTCTGAGG CTTTGGAGCA GCCTCGGTTT  
TGGCCTTCTT TAAGGATCTC TAAGCTAGCA GTAAGTAGCC TAGCCATGCT GTTGTAGGAA  
GTTGTTGCTT CATCCTGGCT CCAGCACAAA GGCAGTCACT AAACGTGGC CTCATTTTCAT  
CAGAGCTGAA TGCAAATTCC TTGTGCTCTT CCTGTGTCCT CCTGGAAC

## Sequence 4

AGTTGGGGAC ACAGCTTGCT TGATTAAGAT GTTCTTGGG AAAAGGAGTT AAGCCTAATG  
ATTTCCAATG GAAAGGACTG CTAATTGGGG AGGCAATGTT GCTTAATTGG GACACCTGCG  
GGTAATTAAA AGCTCTCTCC CAGTGGCCTT TCCTGTTTTT GGCTCTGGGA GGCGAAGGCA  
TTGAGAGGGA TGCAGGCATT CTAAGGGCTG GTTCTTGGTT TCTCCCTTCC CCTCTGTCCA  
AACTCAGTGA GGTATCCCTG TCTGTGCTGT CCTTAGAGTG CCGTCCTGAG GCCTTGGTGA  
GTTAAGGTCT CTGGATCTGA GCTGCCTCAG GGAAACGCAT GAGCTCATTG GAAAGGGGAG  
AACCAGGCAA AGGTGTTGGC TGTGACCTCA GAATTCTGAG GGGCAAAGGT TCAAGGCTAA  
CTCTCATTAT AGAGCAAGTT TGAGACTGGC CTGGGAACAA AAATATAAAG TGAGTGAGGT  
CATATGACAG CACCTGAGGA GTCCTGTCCC TAGAGATCAT AAGGACCTGG CTGCTGGGGA  
CTTGTTGCAG ATGGCACTTT GTGTCGAGAG AGGGGACCTG CCCCAGCATG GGAGGCCCTG  
GAAGATCCTC TGGATTAACT GTGAACACTG ATTGCTGCTT TATACCTGGA GTTGTGCTGT  
TATCTGGTAC ACATCTGCTG GGTGAATGAG TTCATGGGCT TTATTTTCAGT GAGGTATTTA  
CCTGAGGAGA AAGAAGGACT GGTGCCACAA AGCACAGCTT TTAAATCTGT GGGTTGTGAC  
CCATTATGGA CTATCATAAC TGAGTGCAGG TATCAAGAAT ACTTTAGCAG GTGGTAAAAA  
GATTTTTGAA TGCGCAACGA CCAAACTGA ACTCAAAAAT CAAGCATGGC ATGGATCCTG  
GGTGCTCCTG GAAGCACTTG CTTTACTGC ATTGTGCGAC TTGACGGTAG CCTTGGTTCT  
GAATGCACAA CACGTGGGCT TTGGGCTGCA CAGGCCACCA CGCCGTGCCT GAAACACCTC  
AGCTCAGGTT TGTGGCTATG TCCTATGACT TGGACTTACT TTTATTGCAC ATATAAATAT  
TTTCTGCTG

## Sequence 5

GAGGGGGTGG TGGCACAGTT ATGTTTTTGT AGGAAGGGTT CCATGAACCT CAGCAGAGCT  
 CGGGTTAGAA ATTTAAAAGC CCTGAGGGGA ATTTTTTTTTT TAAATCGCTA TGAATCTGAC  
 ATGAGAAAAA CAGATCAGAA ACGTTCTTGT GCTTCAGAAA AGGACAAGTG TGTGAGCTAA  
 CAGACTGCAC ACTGGTGTTC GAGGCACATC TGGATCACAG GAGCGTCAGA TAATGTCCCC  
 AAAGGTAAAT GCATTTGCTT GCACAGTACC GAGTGTGGTG GGGGGTGCCT ACAGCCCAGC  
 GGTCTCAAC CTTCCTGATG CTTGACCCCT TTAATACAGT GCCTCATGCT CTGGTGACCT  
 CCCCACCTT AAAATTATTT TTGTTGCTGT TCATAACTGT GATTTTGATA CTGTTATGAA  
 TTGTAATATA AATAATTTTG AAGAAAGAGG TTTGCCAAGG GTTTGAGAAC TGCTGTTCTA  
 GCCCCACGTG GATGGTTTTT CGTCATTTGG GGTTTTTTATG AGGCAGAGTC TTATGTAGCC  
 CAGGCTAGCA GCCTAGAATG TGCTACTTAG CTGAGGAATA ACCTTGGAAC TTCTGAGGAC  
 TGGAGAGACT GGCTTAGTCC TCAAGAAACT GGAAATAGCT GGAGTTTGGC TACTTGTGGG  
 TTCCTTTTTC TTCAAACCTT TTCTACTCTT TTTCCACCCT GTCGGCCCCC TAACACTAAA  
 TAAGAAAAGAG AAAGGGGAGC ATAGAGGGGA AAAGAAACCC CTGAATAACG TCAGTAGTTG  
 GCAAAGGGGG GTGACATATG TTGTCATTAG ACCACATCCT GGTGATTAAG GGGAGTCAAG  
 TTCCTTGGGG CAAGTTTGAT CTTTCGTGTA ACGATATCTA ATTTCTTCTC CCTGTTGCTT  
 CGTCTTTGTG AACACGACT TGATAACCCA CAATGGACCA TCAACCAACC AACCAACCAT

## Sequence 6

TTGTCTCTGG TGTTACTTGT TTTCCCAATT CTGACAGTGG TTTGACCTT CTATACGCCT  
 GTGTGTCAGG AGTGCTGTAG ACCTATTTTC CTGTTTTCTT TCAGCCAGTT ACAGGAACAG  
 AGTGTTCTAC TGTCAGATGT GTAGCTGTTC CTGTCCACTG ACTTTCAAGC TGTCTCTGTG  
 TGCAGGAACC AGAAGGGCCT GTCCCTACTT CTACTGGGCC CCTACGCACA GGGGGCCTAG  
 ATGGTGCTAG GTGTTTTTCT CTAGAGCCTG AAATGTGGGC AGAGAGTAGT CTCCTCTGGT  
 TTCCTAGGTA TGTCTTCCCC TCTGAAGGTC TAGCTCTCCC TTCCATGGGA TATGGGTGCA  
 GGGAGCTGTT TGACCAGGTC CTCTCAAATC CGGGTGCAGT CTGGACCGCA GGCTCCTGTA  
 GCTTGCCTGC TGCAATCTTC CCGCACCCAG AGGCACCCAA GTTTCCTCTT GGGCCAAGGA  
 TGTGGGCAAA GGTGGGCAGA AGTGGCAATC TCTCCTGCCC TAGCGTCTCA GGATTGCCCT  
 CACTTCTGGG CAATCCGCTC TCTCTTCCAC AGGGTTTGGG AGCAGGGAGC TGTGGGCGCG  
 TATCAGGCAA AGGTTTGAGG CAACCAGTTA GAAACTGGAA GTGTCAGGTC CCAGAGGAAT  
 TTTGCCTTTG TGTGTCCTGA GTCCACCAGG CAGGTCACCT GGAGCAGAAA AATTGGTTTT  
 CCCCTCGGTC TCAGGCCTGA AGTGCACCT CAGGGTTGGC TTTCAGCTGT ACCTGTGGAA  
 AGTATGGTTT TAAAAATCTA AGATAGCTAT CATGCAGCAA GGCTTGTGTA AAATGTCTAT  
 TTGGTTCCTT TATGACTTAC TTTTGCTGTA CTGAGGATCA AACCTAGGGT CTCAAGCAGT  
 CATCACAATT CTCTGTCACT GATCCAGCTC CATTTCTATT TTCTTTTGTC CCGCGCGATC  
 TCTCGCCAGC AAGAAAACAC GCTAGGGACA TACGAATCCT TGCTGCAGCC AAAACTTTTA  
 TTGAATCTTA AGGAGAAGCC CGCGCACCGG ACTGGCGCGG TTTATATACA CCCTAGCACA  
 GTGCATCCAC A



CLAIMS

1. A method of screening and recovering a regulatory DNA capable of inducing metastasis comprising the steps of:

i. transferring tagged fragments of a human DNA from malignant, metastatic cancer cells into a cell line that produces only benign, non-metastasizing tumours when injected into a syngeneic animal;

ii. injecting the transformed cells into the syngeneic animal;

iii. selecting those animals in which metastasizing tumours have been identified; and

iv. recovering the regulatory DNA capable of inducing metastasis therefrom.


2. A method as claimed in claim 1 in which the fragments of human DNA transferred in step 1 are from 0.1 to 50 kilo base pairs in length.

3. A method as claimed in claim 2 in which the fragments of human DNA transferred in step (i) are less than 1.6 kilo base pairs in length.

4. A method as claimed in claim 1, 2 or 3 in which the cell line that produces only benign non-metastasizing tumours is a rat mammary epithelial cell line.

5. A method as claimed in claim 4 wherein the rat mammary epithelial cell line is a Rama 37 cell line.

6. A method as claimed in claim 5 wherein the tag is an oligonucleotide sequence:



AMENDED SHEET

7. A regulatory DNA capable of inducing metastasis consisting essentially of a human DNA fragment of less than 1.6 kilobase pair in length obtained from a malignant, metastasis cancer cell.

8. DNA consisting essentially of a regulatory DNA capable of inducing metastasis from sequence 1:

C2

CTTCCTTGGT	GCTCTATGTC	TGCTCTCTCC	CCTTCTCCAG	TCCCATTAAG	GCATAACCAT
CTTGACAGAC	TCTGGGACAG	TCCCCTCTGC	TCTCCTGTTG	GCGCCTGAGT	CCCTTTTTTGC
CTGAGGACCC	TTACCGTAGC	CTCCCATCTG	GATGACCTAG	TAGAAGACGT	GGGAAGTTGT
CACACTCAGG	TAAC TGAGCA	GAGCTCAGAG	ATTTAAAGTG	AGTCTGGGGA	GCCTCGAGGA
TTGATCTGCT	GCCTTAAAAA	GCCAAATTGGA	TGACTAACCC	AGACTATTGT	CACCTTAGGT
GCGAAGTCAC	TAGCATATCT	GATGGGTCAC	ATCTGAGAAA	GGTTTCTAGC	AGTGGTGGCC
TTGTGTGAGC	AGCATGGCGT	GTATCATGGT	GTGCAGCATA	CTCAGGCTGC	TTGCAACACT
CGAGGCTCTT	CTTCAGTATT	AGGGGAACCA	CTGGTGTTSG	AACATGGTCC	AAGAATACAG
TCATGTGAGG	AGAATCCCAA	TGCGTCAGGA	GAAAACGAGA	GTCTGTGACC	TCCATTCTTC
AAGATACAGA	AFTATTCTTG	GACTGTGTTT	TCATGCTCCT	TGTGGATGGG	AGTGAGTTTA
CTTCAGGTTA	ATCAGCATTG	CTTACTGTTG	GTATTCAAGT	AAATGCTTAA	ATTATCCTGG
ATATACCTCT	GTGGCAAGCA	GGTTTITGAT	ACATGCAGCT	TGTCCTTGTG	ATTGATACTG
CTTGAACTCA	AGAGAACTTT	GCTCATGTGA	TCTTTCTTAA	CCGATGGAGT	AGAAACTGTC
TGATGCTCTC	AATAAAGTTG	GCTCTTGAC	GAGACGTTAG	TCTGTCTCTG	TTATCTGCTC
CATTCTTCCG	CTCCACGGC	CTCTACAGCA	CTAAACCCAC	CACCGATAGA	CTCAGTCTTT
CAC TGACAAA	CATCACCAGA	GGCTCTTAAC	TGAGATTATA	AACTGTTACT	AGATGATGGG
TGGAATCGCT	CCCCAGAAAC	ATAAACATTT	ACTTGGAGAA	CTCAAGACCC	CTTTGTAGAC
ATAACTCCCA	TGGT				

9. DNA consisting essentially of a regulatory DNA capable of inducing metastasis from sequence 2:

C5

ATTGCTGTGA	GCCTATTAGC	GACATTTGGT	GACGCCCCCTT	TTAAGGGGGT	AGATACAAAG
AATGGGTTGA	AATTCTGTGC	CACAAACGCT	CTCCATGTTT	TCACAATTAC	ACTTGCAACC
TGTGGTCAGC	AGCCAGAAAT	TAGGGATGTG	ATGGGACAGG	GTCCGGGAAA	GAAGGAGAAG
GGTAAAGGAA	AGACAGCACG	TTAAAGTCCA	AACAGCTCCA	GGAGACTATC	TGTAGAAATA
ACATCAGACC	ATGAGGAGAA	TTGATATCAT	TGTTTTTCAA	TGGGTATCGC	CAAGGGGACT
TTCCATCTGA	TTAATAATAA	TTACTGCTGG	CACTAAATCC	AATTGGAAAT	GCCCCACACA
ATTTATCTTC	CACTTCATGC	TGCTACCATA	TGCCTGACGT	GGCGGAGCAG	AAGCATTCCC
TCCCGTTCTG	ATAAATAGTA	CTTTGTAAAT	ATTTGGAGAC	GGGAGCTCTG	GTGACAGGGA
ACACGTACAA	ACCGGCCTGT	TTATCATGTT	CCCGATAGAG	GCCCTCTTTG	ACGTACAGGA
CCCCAAAACA	GTCAGGATGC	TGTGAATTTT	CTTCCATGAA	GCCTTGTTCA	CAATTAGCAA
CCATTGGAGG	AAGCAGGCTG	CACTGTCTAC	CACAAGTGGC	ACTTTCCAAA	GAGCACACAT
ATATTGGAGC	AAGACATTTT	GCTGGCTGAC	TGGTGCTGTG	TAAGCTGATA	AACTGCTATA
TTTATTAAAC	TGGCTTTTCT	TTGAACACCC	CACTCAAGGA	AAAAAAAACA	CACCTTAGGGT
GACATTATTT	GGAGATGAAG	TCTTTATAGA	GATGCTTAA	TTTAAACGAG	ACTTTTAAAG
CCGGCTCTAT	TCCATTTAAT	GAATGGTGTC	CCTACAAAGG	AAGAAACTGG	GACAGAGGTA
TGTACACTTG	TGTGTGTGTG	AGAGACACG	TGAGGAGCTG	AAGAGGAGCA	CGTACAAGTC
AGAGAAAGGC	TGACCCCTTAT	TCACACTGAG	CAAACCAAGC	ATGTGTGGGT	CGATAGATGA
GAGTATCCCC	CAAGACTCAC	ACATTCGAAC	GCTTGGTC		



10. DNA consisting essentially of a regulatory DNA capable of inducing metastasis from sequence 3:

C6

AGGACCAGAG	TTCACATCCC	ATCAAATGGC	CCAGAAGGTT	TTAATGCTGT	CTTTTGGCCC
AGGGGCGAAC	TGCACACACA	TGTGCACATA	CACTTACAGA	GACACACATT	CAGCAGCATA
AGAACACAT	CACAAATAAA	AAAAATCTTG	AAAAATTTTA	AGCTAAAATT	GTTAAGAAAT
AACATATATA	CAATTTTTCT	TTATTTTTTT	AAAGATTTAT	TTATTTAATG	TATATCAGTA
CACTGCCTCT	CCCTCCAGAC	ATAGCAGTAC	AGGGCATCGG	ATCCCATTAC	AGATGGTTGT
GAGCCACCAT	GTGGTTTCAC	AGATGGTTGT	GAGCCACCAT	GTGGTTTCAG	GAATTGAACT
CAGGACCTTT	GGAAGAGCAG	TCAGTGCTCT	TAACCTCTAA	GCCATCTCTC	CTGACCCCTA
TATACAATTT	TAATGCTACG	TACACACAA	TTCTCTTTCC	TTTAATGGTT	GAGATTTTTG
TCTGGAGAAG	TAAGAAATAA	GGAGGGAAAG	AACATTGCTT	TCACATTGCA	CCAGTGGGAA
CAGCGTGTTT	AAAGTAGGAA	TGCCATGAAA	TGACTGGCCT	GCCTTCTCAT	TACTGTTCTT
CCCCTCCTC	CTTTTAACTG	GAGCTCCTTT	ATCTAATTTA	TTAGTTTGAC	GATACCCAGG
GTTTTCTTCT	GTTTTGATCT	TTTTAAGACA	GAGACTCACC	ATATAGCCCT	GGCTGGCCTG
AAGCTCACTA	TGTAGACCAG	TCTGGCCTTG	AACTCAAAGG	AGATCTATCT	GCTTCCTAGT
GCTGGGATTA	AAGGCTTGTT	CTACCAAGTC	TGGTCTGAGG	CTTTGGAGCA	GCCTCGGTTT
TGGCCTTCTT	TAAGGATCTC	TAAGCTAGCA	GTAAGTAGCC	TAGCCATGCT	GTTGTAGGAA
GTTGTTGCTT	CATCCTGGCT	CCAGCACAAA	GGCAGTCACT	AAACGTGGGC	CTCATTTTCAT
CAGAGCTGAA	TGCAAATTCC	TTGTGCTCTT	CCTGTGTCCT	CCTGGAAC	

11. DNA consisting essentially of a regulatory DNA capable of inducing metastasis from sequence 4:

C9

AGTTGGGGAC	ACAGCTTGCT	TGATTAAAGAT	GTTTCTTGCG	AAAAGGAGTT	AAGCCTAATG
ATTTCCAATG	GAAAGGACTG	CTAATTGGGG	AGGCAATGTT	GCTTAAATGG	GACACCTGCG
GGTAATTAAT	AGCTCTCTCC	CAGTGGCCTT	TCCTGTTTTT	GGCTCTGGGA	GGCGAAGGCA
TTGAGAGGGA	TGCAGGCATT	CTAAGGGCTG	GTTCTTGGGT	TCTCCCTTCC	CCTCTGTCCA
AACTCAGTGA	GGTATCCCTG	TCTGTGCTGT	CCTTAGAGTG	CCGTCTTGAG	GCCTTGGTGA
GTTAAGGTCT	CTGGATCTGA	GCTGCCTCAG	GGAAACGCCAT	GAGCTCATTG	GAAAGGGGAG
AACCAGGCAA	AGGTGTTGGC	TGTGACCTCA	GAATTCTGAG	GGGCAAAGGT	TCAAGGCTAA
CTCTCATTAT	AGAGCAAGTT	TGAGACTGGC	CTGGGAACAA	AAATATAAAG	TGAGTGAGGT
CATATGACAG	CACCTGAGGA	GTCCTGTCCC	TAGAGATCAT	AAGGACCTGG	CTGCTGGGGA
CTTGTTGCAG	ATGGCACTTT	GTGTGAGAG	AGGGGACCTG	CCCCAGCATG	GGAGGCCCTG
GAAGATCCTC	TGGATTAACT	GTEAACACTG	ATTGCTGCTT	TATACCTGGA	GTTGTGCTGT
TATCTGGTAC	ACATCTGCTG	GGTGAATGAG	TTTATGGGCT	TTATTTTCACT	GAGGTATTTA
CCTGAGGAGA	AAGAAGGACT	GGTGCCACAA	AGCACAGCTT	TTAAATCTGT	GGGTTGTGAC
CCATTATGGA	CTATCATAAC	TGAGTGACAG	TATCAAGAAAT	ACTTTAGCAG	GTGGTAAAAA
GATTTTTTGA	TGCGCAACGA	CCAAAACCTG	ACTCAAAAAAT	CAAGCATGGC	ATGGATCCTG
GGTGCTCCTG	GAAGCACTTG	CCTTTACTGC	ATTGTGCGAC	TTGACGGTAG	CCTTGGTTCCT
GAATGCACAA	CACGTGGGCT	TTGGGCTGCA	CAGGCCACCA	CGCCGTGCCT	GAAACACCTC
AGCTCAGGTT	TGTGGCTATG	TCCTATGACT	TGGACTTACT	TTTATTGCAC	ATATAAATAT
TTTCCTGC					

12. DNA consisting essentially of a regulatory  
DNA capable of inducing metastasis from sequence 5:

C12

GAGGGGGTGG	TGGCACAGTT	ATGTTTTTGT	AGGAAGGGTT	CCATGAACCT	CAGCAGAGCT
CGGGTYAGAA	ATTTAAAAGC	CCTGAGGGGA	ATTTTTTTTT	TAAATCGCTA	TGAATCTGAC
ATGAGAAAAA	CAGATCAGAA	ACGTTCTTGT	GCTTCAGAAA	AGGACAAGTG	TGTGAGCTAA
CAGACTGCAC	ACTGGTGTTT	GAGGCACATC	TGGATCAGAG	GAGCGTCAGA	TAATGTCCCC
AAAGGTAAAT	GCATTTGCTT	GCACAGTACC	GAGTGTGGTG	GGGGGTGCCT	ACAGCCCAGC
GGTTCTCAAC	CTTCCTGATG	CTTCGACCCT	TTAATACAGT	GCCTCATGCT	CTGGTGACCT
CCCCAACCTT	AAAATTATTT	TTGTTGCTGT	TCATAACTGT	GATTTTGTATA	CTGTTATGAA
TTGTAATATA	AATAATTTTG	AAGAAAGAGG	TTTGCCAAGG	GTTTGAGAAC	TGCTGTTCTA
GGCCCACTTG	GATGGTTTTT	CGTCATTTGG	GGTTTTTTATG	AGGCAGAGTC	TTATGTAGCC
CAGGCTAGCA	GCCTAGAATG	TGCTACTTAG	CTGAGGAATA	ACCTTGGAAC	TTCTGAGGAC
TGGAGAGACT	GGCTTAGTCC	TCAAGAAACT	GGAAATAGCT	GGAGTTTGGC	TACTTGTGGG
TTCCTTTTTC	TTCAAACCTT	TTCTACTCTT	TTTCCACCCT	GTCGGCCCCC	TAACACTAAA
TAAGAAASAG	AAAGGGGAGC	ATAGAGGGGA	AAAGAAACCC	CTGAATAACG	TCAGTAGTTG
GCAAAGGGGG	GTGACATATG	TTGTCATTAG	ACCACATCCT	GGTGATTAAAG	GGGAGTCAAG
TTCCCTGGGG	CAAGTTTGAT	CTTTCGTGTA	ACGATATCTA	ATTTCTTCTC	CCTGTTGCTT
CGTCTTTGTG	AACACGACT	TGATAACCCA	CAATCGACCA	TCAACCAACC	AACCAACCAT

13. DNA consisting essentially of a regulatory  
DNA capable of inducing metastasis from sequence 6:

C20

TTGTCTCTGG	TGTTACTTGT	TTTCCCATTT	CTGACAGTGG	TTTGACCTT	CTATACGCCT
GTGTGTCAGG	AGTGCTGTAG	ACCTATTTTC	CTGTTTTCTT	TCAGCCAGTT	ACAGGAACAG
AGTGTTCTAC	TGTCAGATGT	GTAGCTGTTC	CTGTCCACTG	ACTTTCAGC	TGTCTCTGTG
TGCAGGAACC	AGAAGGGCCT	GTCCCTACTT	CTACTGGGCC	CCTACGCACA	GGGGGCCTAG
ATGGTGCTAG	GTGTTTTTCT	CTAGAGCCTG	AAATGTGGGC	AGAGAGTAGT	CTCCTCTGGT
TTCCTAGGTA	TGTCTTCCCC	TCTGAAGGTC	TAGCTCTCCC	TTCCATGGGA	TATGGGTGCA
GGGAGCTGTT	TGACCAGGTC	CTCTCAAATC	CGGGTGCACT	CTGGACCGCA	GGCTCCTGTA
GCTTGCCCTGC	TGCAATCTTC	CCGCACCCAG	AGGCACCCAA	GTTTCCTCTT	GGGCCAAGGA
TGTGGGCAAA	GGTGGGCAGA	AGTGGCAATC	TCTCCTGCCC	TAGCGTCTCA	GGATTGCCCT
CACTTCTGGG	CAATCCGCTC	TCTCTTCCAC	AGGGTTTGGG	AGCAGGGAGC	TGTGGGCCGG
TATCAGGCAA	AGGTTTGAGG	CAACCACTTA	GAAACTGGAA	GTGTCAAGTC	CCAGAGGAAAT
TTTGCCCTTTG	TGTGTCCCTGA	GTCCACCAGG	CAGGTCACCT	GGAGCAGAAA	AATTGGTTTTT
CCCCTCGGTC	TCAGGCCTGA	AGTTGCACCT	CAGGGTTGGC	TTTCAGCTGT	ACCTGTGGAA
AGTATCGTTT	TAAAAATCTA	AGATAGCTAT	CATGCAGCAA	GGCTTGTTGTA	AAATGTCTAT
TTGGTTCCCT	TATGACTTAC	TTTTGCTGTA	CTGAGGATCA	AACCTAGGGT	CTCAAGCAGT
CATCACAATT	CTCTGTCACT	GATCCAGCTC	CATTTCTATT	TTCTTTTGTG	CCGCGCGATC
TCTCGGCAGC	AAGAAAAACAC	GCTAGGGACA	TACGAATCCT	TGCTGCAGCC	AAAACCTTTTA
TTGAATCTTA	AGGAGAAGCC	CGCGCACCGG	ACTGGCGCGG	TTTATATACA	CCCTAGCACA
GTGCATCCAC	A				

14. The use of an osteopontin gene as a  
metastasis inducing transformant.

16. A kit for diagnosing the likelihood of a cancer metastasizing comprising a probe as claimed in claim 15 and one or more of a colour indicator, an oligonucleotide primer, materials for gel analysis and materials for DNA transfer or hybridisation.

AMENDED SHEET

1/8

Table 1

Donor DNA	Cells injected	No. rats	Tumours	%	Metastasis	%
None	Rama 37	46	22	48%	0	0%
Human metastatic	R37-Ca2-LT1	20	18	90%	6 <sup>b</sup>	33%
Human benign	B-T1	18	18	100%	0	0%
Human/rat metastatic tagged	R37-Ca2-HT	37	29	78%	6 <sup>b</sup>	21%
Human/rat metastatic	R37-Ca2-H	31	24	77%	4 <sup>b</sup>	17%
Human/rat benign tagged	R37-B-HT	39	31	79%	0	0%
PCR fragment F1	R37-F1	30	28	93%	12 <sup>b</sup>	43%
PCR fragment F2	R37-F2	40	36	90%	9 <sup>b</sup>	25%

Table 2

Transfecting DNA <sup>a</sup>	<i>opn</i> mRNA <sup>b</sup>	No. of rats	% Metastasis <sup>c</sup>
pSV2 <i>neo</i>	1	26	0
C2-DNA	2.5 <sup>d</sup>	18	33 <sup>e</sup>
C5-DNA	1.6 <sup>d</sup>	25	12
C6-DNA	1.6 <sup>d</sup>	18	50 <sup>e</sup>
C9-DNA	4.4 <sup>d</sup>	23	17 <sup>e</sup>
C12-DNA	2.8 <sup>d</sup>	13	23 <sup>e</sup>
C20-DNA	1.8 <sup>d</sup>	13	23 <sup>e</sup>
C9-DNA Lung metastatic line	16 <sup>d</sup>	24	29 <sup>e</sup>
CMV-1	1.1	24	0
OPN-1	6.0 <sup>d</sup>	42	55 <sup>e</sup>




FIG. 1


09/101423

WO 97/25443

PCT/GB97/00074

4/8

HLu Ca2 B  
HT HT HT



F2  
F1

FIG. 2




FIG. 3






FIG. 4 A




FIG. 4 B

09/101423




FIG. 5 a




FIG. 5 b




FIG. 5 c




FIG. 5 d




FIG. 6

<p><b>DECLARATION FOR UTILITY OR DESIGN PATENT APPLICATION</b></p> <p><input type="checkbox"/> Declaration OR Submitted with Initial Filing</p> <p><input checked="" type="checkbox"/> Declaration Submitted after Initial Filing</p>	Attorney Docket Number	WPT 0114 PUSA
	First Named Inventor	Philip S. Rudland
	<b>COMPLETE IF KNOWN</b>	
	Application Number	09/101,423
	Filing Date	July 9, 1998
	Group Art Unit	Unknown
	Examiner Name	Unknown

As a below named inventor, I hereby declare that:

My residence, post office address, and citizenship are as stated below next to my name.

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled:

METASTASIS INDUCING DNA'S

The specification of which

(Title of the invention)

☐ is attached hereto  
OR

☐ was filed on (MM/DD/YYYY)

January 10, 1997

as United States Application Number or PCT International

Application Number PCT/GB97/00074 and was amended on (MM/DD/YYYY) (if applicable).

I hereby state that I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment specifically referred to above.

I acknowledge the duty to disclose information which is material to patentability as defined in Title 37 Code of Federal Regulations, § 1.56.

I hereby claim foreign priority benefits under Title 35, United States Code § 119 (a)-(d) or § 385(b) of any foreign application(s) for patent or inventor's certificate, or § 385 (a) of any PCT International application which designated at least one country other than the United States of America, listed below and have also identified below, by checking the box, any foreign application for patent or inventor's certificate, or of any PCT International application having a filing date before that of the application on which priority is claimed.

Prior Foreign Application Number(s)	Country	Foreign Filing Date (MM/DD/YYYY)	Priority Not Claimed	Certified Copy Attached?	
				YES	NO
9600470.0	Great Britain	January 10, 1996 (01/10/96)	<input type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/>	<input type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/>	<input checked="" type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/>

☐ Additional foreign application numbers are listed on a supplemental priority sheet attached hereto:

I hereby claim the benefit under Title 35, United States Code § 119(e) of any United States provisional application(s) listed below.

Application Number(s)	Filing Date (MM/DD/YYYY)	<input type="checkbox"/> Additional provisional application numbers are listed on a supplemental priority sheet attached hereto.

## DECLARATION

I hereby claim the benefit under Title 35, United States Code §120 of any United States application(s), or §365(a) of any PCT international application designating the United States of America, listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States or PCT international application in the manner provided by the first paragraph of Title 35, United States Code §112, I acknowledge the duty to disclose information which is material to patentability as defined in Title 37, Code of Federal Regulations §1.56 which becomes available between the filing date of the prior application and the national or PCT international filing date of this application.

U.S. Parent Application Number	PCT Parent Number	Parent Filing Date (MM/DD/YYYY)	Parent Patent Number (if applicable)

☐ Additional U.S. or PCT international application numbers are listed on a supplemental priority sheet attached hereto.

As a named inventor, I hereby appoint the following registered practitioner(s) to prosecute this application and to transact all business in the Patent and Trademark Office connected therewith:

Name	Registration Number	Name	Registration Number
William G. Conger	31,209		
John E. Nemazi	30,876		
James A. Kushman	25,634		

☒ Additional registered practitioner(s) named on a supplemental sheet attached hereto.

Direct all correspondence to:

Name: William G. Conger  
Address: 1000 Town Center, Twenty-Second Floor  
City: Southfield State: MI ZIP: 48075  
Country: USA Telephone: (248) 358-4400 Fax: (248) 358-3351

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Name of Sole or First Inventor:

☐ A petition has been filed for this unsigned inventor

Given Name: PHILIP Middle Initial: S Family Name: RUDLAND Suffix e.g. Jr.: PROF

Inventor's Signature: Philip Steven Rudland Date: 21/7/98

Residence: City: Liverpool State: Country: GB2 Citizenship:

Post Office Address:

Post Office Address:

City: State: Zip: Country:

☒ Additional inventors are being named on supplemental sheet(s) attached hereto

Please type a plus sign (+) inside this box → ☐

PTO/SB/01 (8-95)  
Approved for use through 9/30/98. OMB 0851-0032  
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE  
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

## DECLARATION

## ADDITIONAL INVENTOR(S) Supplemental Sheet

Name of Additional Joint Inventor, if any:				<input type="checkbox"/> A petition has been filed for this unsigned inventor			
Given Name	200 ROGER	Middle Initial	B	Family Name	BARRACLOUGH	Suffix	e.g. Jr.
Inventor's Signature	Barry Roger Barracough				Date	20/7/98	
Residence: City	LIVERPOOL	State		Country	GB	Citizenship	
Post Office Address							
Post Office Address							
City		State		Zip		Country	
Name of Additional Joint Inventor, if any:				<input type="checkbox"/> A petition has been filed for this unsigned inventor			
Given Name		Middle Initial		Family Name		Suffix	e.g. Jr.
Inventor's Signature					Date		
Residence: City		State		Country		Citizenship	
Post Office Address							
Post Office Address							
City		State		Zip		Country	
Name of Additional Joint Inventor, if any:				<input type="checkbox"/> A petition has been filed for this unsigned inventor			
Given Name		Middle Initial		Family Name		Suffix	e.g. Jr.
Inventor's Signature					Date		
Residence: City		State		Country		Citizenship	
Post Office Address							
Post Office Address							
City		State		Zip		Country	
Name of Additional Joint Inventor, if any:				<input type="checkbox"/> A petition has been filed for this unsigned inventor			
Given Name		Middle Initial		Family Name		Suffix	e.g. Jr.
Inventor's Signature					Date		
Residence: City		State		Country		Citizenship	
Post Office Address							
Post Office Address							
City		State		Zip		Country	
Name of Additional Joint Inventor, if any:				<input type="checkbox"/> A petition has been filed for this unsigned inventor			
Given Name		Middle Initial		Family Name		Suffix	e.g. Jr.
Inventor's Signature					Date		
Residence: City		State		Country		Citizenship	
Post Office Address							
Post Office Address							
City		State		Zip		Country	

☐ Additional inventors are being named on supplemental sheet(s) attached hereto

Please type a plus sign (+) inside this box →



PTO/SB/01 (8-96)  
 Approved for use through 9/30/98, OMB 0851-0032  
 Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE


Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

**DECLARATION**
**REGISTERED PRACTITIONER  
 INFORMATION  
 (Supplemental Sheet)**

Name	Registration Number	Name	Registration Number
Bernie L. Brooks	26,260	Robert C. Brandenburg	29,048
James A. Kushman	25,634	Paul M. Schwartz	33,278
David P. Syrowik	27,956	James R. Ignatowski	26,741
Mark A. Cantor	30,614	A. Frank Duke	20,937
Ralph M. Burton	17,748	Timothy G. Newman	34,228
John A. Artz	25,824	John M. Halan	35,534
Robert C.J. Tuttle	27,962	Jeffrey M. Szuma	35,700
Earl J. LaFontaine	30,766	Frank A. Angileri	36,733
Ronald M. Nabozny	28,648	William G. Conger	31,209
Thomas A. Levy	30,770	Robert C. Jones	35,209
John E. Nemazi	30,876	Rhonda L. McCoy-Pfau	37,887
Kevin J. Heind	29,805	Christopher W. Quinn	38,274
William G. Abbatt	31,936	David S. Bir	38,383
Donald J. Harrington	17,427	Sangeeta G. Shah	38,614
Frederick M. Ritchie	18,669	Konstantine J. Diamond	39,657
Keith M. Zerschling	18,496	John S. Artz	36,431
Hugo Delevie	32,688		



United States Patent & Trademark Office  
Office of Initial Patent Examination – Scanning Division



SCANNED

Application deficiencies were found during scanning:

☐ Page(s) 4 of 5 of Declaration were not present  
for scanning. (Document title)

☐ Page(s) \_\_\_\_\_ of \_\_\_\_\_ were not present  
for scanning. (Document title)

☐ Scanned copy is best available.